Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laromustine plus standard induction vs standard induction in newly diagnosed AML/MDS
2008-000404-92Phase 3Terminated
- Sponsor
- HOVON
- Start
- Jun 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of laromustine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by HOVON. Primary endpoints: Dose limiting toxicity of Laromustine combination (Part A) and Duration of myelosuppression (Part A). Started Jun 2008; status: terminated.
02
Drugs
laromustine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2008-000404-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000404-92.